Your browser doesn't support javascript.
loading
Advances in the treatment of atherosclerosis with ligand-modified nanocarriers.
Deng, Xiujiao; Wang, Jinghao; Yu, Shanshan; Tan, Suiyi; Yu, Tingting; Xu, Qiaxin; Chen, Nenghua; Zhang, Siqi; Zhang, Ming-Rong; Hu, Kuan; Xiao, Zeyu.
Afiliação
  • Deng X; Department of Pharmacy The First Affiliated Hospital of Jinan University Guangzhou China.
  • Wang J; The Guangzhou Key Laboratory of Basic and Translational Research on Chronic Diseases Jinan University Guangzhou China.
  • Yu S; Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences Southern Medical University Guangzhou China.
  • Tan S; Department of Pharmacy The First Affiliated Hospital of Jinan University Guangzhou China.
  • Yu T; The Guangzhou Key Laboratory of Basic and Translational Research on Chronic Diseases Jinan University Guangzhou China.
  • Xu Q; Department of Pharmacy Zhujiang Hospital Southern Medical University Guangzhou China.
  • Chen N; Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences Southern Medical University Guangzhou China.
  • Zhang S; Department of Pharmacy The First Affiliated Hospital of Jinan University Guangzhou China.
  • Zhang MR; The Guangzhou Key Laboratory of Basic and Translational Research on Chronic Diseases Jinan University Guangzhou China.
  • Hu K; Department of Pharmacy The First Affiliated Hospital of Jinan University Guangzhou China.
  • Xiao Z; The Guangzhou Key Laboratory of Basic and Translational Research on Chronic Diseases Jinan University Guangzhou China.
Exploration (Beijing) ; 4(3): 20230090, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38939861
ABSTRACT
Atherosclerosis, a chronic disease associated with metabolism, poses a significant risk to human well-being. Currently, existing treatments for atherosclerosis lack sufficient efficiency, while the utilization of surface-modified nanoparticles holds the potential to deliver highly effective therapeutic outcomes. These nanoparticles can target and bind to specific receptors that are abnormally over-expressed in atherosclerotic conditions. This paper reviews recent research (2018-present) advances in various ligand-modified nanoparticle systems targeting atherosclerosis by specifically targeting signature molecules in the hope of precise treatment at the molecular level and concludes with a discussion of the challenges and prospects in this field. The intention of this review is to inspire novel concepts for the design and advancement of targeted nanomedicines tailored specifically for the treatment of atherosclerosis.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article